Alpha-fetoprotein as a tumor marker in hepatocellular carcinoma: investigations in south Indian subjects with hepatotropic virus and aflatoxin etiologies  by Murugavel, Kailapuri G. et al.
Alpha-fetoprotein as a tumor marker in
hepatocellular carcinoma: investigations in south
Indian subjects with hepatotropic virus and aflatoxin
etiologies
Kailapuri G. Murugavel a,*, S. Mathews b, V. Jayanthi c, Esaki Muthu Shankar a,
R. Hari d, R. Surendran c, Appasamy Vengatesan c, K. Raghuram b,
P. Rajasambandamb, A. Murali c, Usha Srinivas c, K.R. Palaniswamy e,
T. Pugazhendhi b, Sadras Panchatcharam Thyagarajan d,f
International Journal of Infectious Diseases (2008) 12, e71—e76
http://intl.elsevierhealth.com/journals/ijida Infectious Diseases Laboratory, YRG Centre for AIDS Research & Education, VHS Hospital Campus, Taramani, Chennai 600 113, India
bMedical and Surgical Gastroenterology Units of the Government General Hospital, Chennai, India
cGovernment Stanley Medical College and Hospital, Chennai, India
dDepartment of Microbiology, Faculty of Medicine, Dr ALM PG Institute of Basic Medical Sciences, University of Madras,
Taramani Campus, Chennai, India
eDepartment of Digestive Health and Diseases, Government Peripheral Hospital, Chennai, India
f Sri Ramachandra Medical College and Hospital, Porur, Chennai, India
Received 30 November 2007; received in revised form 30 April 2008; accepted 30 April 2008









Objectives: The prevalence of hepatitis B virus (HBV) is reportedly the main cause of hepato-
cellular carcinoma (HCC) in India, where hepatitis C virus (HCV)-associated HCC is believed to be
relatively less prevalent. We verified the usefulness of alpha-fetoprotein (AFP) as a tumor marker
and analyzed the influence of viral etiology on AFP levels in HCC.
Methods: Of a total of 1012 cases with liver disease, 202 were investigated for the presence of
AFP (142 HCC cases, 30 cirrhosis cases, and 30 chronic liver disease (CLD) cases). In addition,
serum samples from 30 healthy patients, 30 hepatitis B surface antigen (HBsAg) carriers, and 30
acute viral hepatitis cases were included as controls. AFP was quantitatively determined using a
commercial ELISA (Quorum Diagnostics, Canada). Out of the 142 HCC cases screened for AFP,
aflatoxin B1 (AFB1) detection was carried out in 38 HCC cases using an in-house immunoperox-
idase test.
Results: In HBV and HCV co-infected HCC cases, the AFP positivity was 85.7%. In HBV alone-
associated HCC, the positivity was 62.9%, and 54.5% of AFB1 positive HCC cases showed AFP* Corresponding author. Tel.: +91 44 22542929; fax: +91 44 22542939.
E-mail address: murugavel@yrgcare.org (K.G. Murugavel).
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positivity. In HBVand HCV negative HCC cases, the positivity was 20.5%, and in HCV-associated HCC it
was 17.6%. The HBV/HCV co-infected group and HBV alone positive HCC cases had significantly
elevated levels of AFP. When AFP positivity was analyzed based on the marker profile of HBV, 89.7% of
AFP positive cases were HBV-DNA positive.
Conclusions: The overall positivity pattern of AFP in HCC does indicate that higher levels of AFP are
observed with hepatitis virus positivity, especially with HBV. Further studies must be carried out to
correlate the serum levels of AFP with the size, number, and degree of differentiation of HCC
nodules.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Hepatocellular carcinoma (HCC) is the fourth leading cause
of cancer-related death worldwide.1—5 The prevalence of
HCC in autopsied Indians is low, and varies between 0.2%
and 1.9%.2 Alpha-fetoprotein (AFP), a 70-KDa glycoprotein
tumor marker, is increased in the majority of patients with
HCC and other gastrointestinal tumors. AFP is normally pro-
duced during fetal development by the liver and yolk sac.
After birth, the levels drop off rapidly, and by the second year
only trace amounts are detectable in serum. AFP may be
useful in the diagnosis and follow-up of cases of HCC,
although increased levels are associated with malignancies
other than primary HCC. Studies suggest that in patients
thought to have HCC on clinical grounds, AFP levels
>400 ng/ml should strongly confirm the presence of HCC
by a tissue diagnosis.6 Some patients with primary hepatic
cancer will have normal AFP levels, and normal or moder-
ately elevated levels should not exclude a diagnosis of HCC,
although the usefulness in follow-up of patients under treat-
ment for hepatoma has not been examined systematically.
Thus, this marker is believed to be useful in following the
clinical course of persons with HCC. It has been suggested
that the AFP values are more likely to be elevated with the
stage of such cancers and are of prognostic value to check the
efficacy of treatment of HCC. Levels of serum AFP are widely
used for HCC screening in patients with chronic liver disease
(CLD). The relationship between viral etiology and AFP levels
in HCC is still unclear. The aim of this study was to verify, in
Indian patients, the usefulness of AFP as a tumor marker, and
to analyze the influence of viral etiology on AFP levels in HCC.
Materials and methods
Study design
This study was conducted between January 1994 and Decem-
ber 1998, after prior approval from the Institutional Review
Board (IRB) of the University of Madras. Written, informed
consent was obtained from all the patients, or their legal
representatives, before study enrolment. The study was
carried out in compliance with good clinical practice, includ-
ing the International Conference on Harmonization Guide-
lines and the Declaration of Helsinki.
Patients and specimens
We analyzed 1012 liver disease cases admitted to the medical
and surgical gastroenterology units of five major hospitals inthe city of Chennai. Inclusion into the study was based on the
clinical diagnosis of HCC, i.e., patients who showed mass
abdomen, mass lesion on ultrasound, and elevated AFP levels
were enrolled. Each subject provided written, informed
consent to conduct an interview, collect a blood specimen,
undergo a liver biopsy, and perform serological assays. All the
cases were interviewed in person with the use of a structured
questionnaire. The subjects were questioned on their socio-
demographic characteristics, diet, cigarette smoking habits,
consumption of alcohol, betel nut chewing, their medical and
surgical history, and any family history of HCC or liver cir-
rhosis. Of the 1012 liver disease cases, 202 were analyzed for
the presence of the tumor marker AFP (142 HCC cases, 30
cirrhosis cases, and 30 CLD cases). In addition, serum samples
from healthy patients (n = 30), hepatitis B surface antigen
(HBsAg) carriers (n = 30), and acute viral hepatitis cases
(n = 30) were used as controls for AFP ELISA.
Serological assays
A 10-ml specimen of blood was collected with the use of a
disposable vacuum syringe and the separated serum kept in a
freezer (70 8C) until assay. The serum specimens were
tested for HBsAg, hepatitis B ‘e’ antigen (HBeAg), anti-
hepatitis B ‘e’ antigen antibodies (anti-HBe), anti-hepatitis
B core antigen IgM antibodies (anti-HBc IgM), hepatitis delta
antigen (HDAg), and anti-hepatitis delta antigen antibodies
(anti-HD) (Wellcozyme, Murex Diagnostics, UK) by ELISA, with
the use of commercially available kits according to the
manufacturer’s instructions. Anti-hepatitis C virus (anti-
HCV) status was tested using RIBA 3.0, SIA in vitro qualitative
enzyme immunoassay (EIA). Aflatoxin B1 (AFB1) detection in
liver biopsies was carried out using an in-house immunoper-
oxidase test on 38 HCC cases.7 The test was sensitive enough
to detect up to approximately 1 ng/ml of AFB1 in serum.7 AFP
in the sera was quantitatively determined using a commercial
ELISA kit procured from Quorum Diagnostics, Canada. This
was a sandwich ELISA; the solid phase was coated with
specific rabbit anti-AFP antibodies. AFP present in the speci-
men will bind to the antibodies in the wells. Then mouse
monoclonal anti-AFP antibody labeled with horseradish per-
oxidase enzyme was added to detect the AFP bound to the
solid phase antibody. A reference standard set containing 0,
5, 20, 50, 150, and 300 ng/ml of AFP in the lyophilized form
was reconstituted before starting the test.
Briefly, 20 ml of standards, specimens, and controls were
added to the appropriate wells. A hundred microliters of zero
buffer was added to each well and mixed for 10 s. Wells were
covered and incubated at room temperature for 30 min.
Table 1 Alpha-fetoprotein positivity profile in hepatocellular carcinoma cases (N = 142)
Study groups AFP positivity Mean titer








HBV positive 62 39 (62.9%) 7.91 502  390 F = 4.09; p = 0.02 1 and 6; p < 0.05
HCV positive 17 3 (17.6%) 1.00 492  215 1 and 6; p < 0.05
HBV and HCV positive 7 6 (85.7%) 28.01 567.7  199.4 1 and 6; p < 0.05
HBV and HCV negative 39 8 (20.5%) 1.2 463.9  390.9 -
AFB1 positive 11 6 (54.5%) 5.6 483  497.7 -
HBV and AFB1 positive 6 3 (50%) 5.67 233.3  194.2 -
AFP, alpha-fetoprotein; OR, odds ratio; SD, standard deviation; ANOVA, analysis of variance; HBV, hepatitis B virus; HCV, hepatitis C virus;
AFB1, aflatoxin B1.
Compared to HCV positive AFP positive subjects, HBV positive AFP positive cases had a 7.91-times greater chance of developing HCC, and
both HBVand HCV positivity revealed a 28.01-times greater chance of developing HCC than HBValone. One-way ANOVA showed the existence
of differences between the five groups analyzed. The Bonferroni t-test also showed that groups 1 and 6 differed significantly.
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times with distilled water. The remaining fluid was removed
by tapping the strips on a tissue paper. Enzyme conjugate
(150 ml) was added to each well and mixed for 5 s. Wells were
incubated for 30 min and the strips were washed. TMB
(3,30,5,50-tetramethylbenzidine) substrate solution (200 ml)
was added to all the wells and the plate was incubated in the
dark at room temperature. Enzyme was stopped by the
addition of 50 ml per well of 2 M H2SO4. The ELISA reader
was blanked in the air and the absorbance was measured at
450 nm (ELx800 ELISA Reader, Biotech Inc., USA). The absor-
bance was measured for each set of reference standards,
specimens, and controls. A standard curve was constructed
by plotting the absorbance obtained from each reference
standard against its concentration (ng/ml). The amount of
AFP (ng/ml) in each specimen was quantitated against the
standard curve obtained by plotting the absorbance of the
reference standards against its concentration.
Statistical analysis was done using Epi Info statistical
software (http://www.cdc.gov/epiinfo/epiinfo.htm). The
positivity profiles of HCC cases in the study groups are given
in frequencies with their percentage. Mean titer values are
given as mean  standard deviation (SD) and the AFP posi-
tivity profiles are given using proportions with 95% confidence
intervals (CI). The positivity profiles of AFP in HCC cases were
analyzed using Chi-square trend and unadjusted odds ratios
(OR). The hepatitis B virus (HBV) marker pattern observed
among the AFP positive and negative HBsAg positive HCC
cases were analyzed using the two sample binomial propor-
tion test, and proportions of percentage with 95% CI are
given. In addition, the AFP levels in AFB1 tissue positive vs.
negative HBV positive and negative cases were analyzed
using Fisher’s exact test. A p-value of <0.05 was considered
statistically significant.
Results
A total of 202 liver disease cases were investigated for the
presence of the tumor marker AFP (142 HCC cases, 30
cirrhosis cases, and 30 CLD cases). All these cases were
screened for HBsAg and anti-HCV to establish HBV and hepa-
titis C virus (HCV) status in addition to certain serological HBV
and HCV markers.8 In addition, serum samples from healthycontrols (n = 30), HBsAg carriers (n = 30), and acute viral
hepatitis cases (n = 30) were used as controls for AFP ELISA.
The male:female ratio of HCC cases in the present study was
6.4:1. The mean age of male HCC cases was 62.7 years as
against 46 years in females. The clinical symptomatology
revealed mass abdomen in 64.1% of cases, while anorexia and
abdomen pain were seen in 43.5% and 35.9%, respectively.
Other common symptoms were pedal edema (27.6%), ascites
(24.7%), weight loss (21.2%), fever (12.9%), and hematemesis
(8.8%). Along with the 142 HCC cases, 30 cases each of
cirrhosis, CLD, HBsAg carriers, and healthy controls were
analyzed for their serum AFP. Among the 142 cases with
HCC screened, 65 (45.8% with CI 38—54%) revealed positive
AFP, while the cirrhosis, CLD, and control groups did not have
detectable AFP levels. Of the total 170 HCC cases, HBV and
HCV co-infection was seen in seven cases (4.1%).
A correlation of AFP positivity with viral marker positivity
is shown in Table 1. In HBV and HCV co-infected HCC cases,
the AFP positivity was 85.7% (n = 6). In HBV alone-associated
HCC, AFP positivity was 62.9% (n = 39), and 54.5% (n = 6) of
AFB1 positive HCC cases showed AFP positivity. In HBV and
HCV negative HCC cases, the AFP positivity was 20.5% (n = 8),
and in HCV-associated HCC it was 17.6% (n = 3). When quan-
titative levels of AFP were analyzed, the HBV/HCV co-
infected group and HBV alone positive HCC cases had sig-
nificantly elevated levels of AFP.
When AFP positivity was analyzed based on the marker
profile of HBV, 89.7% of AFP positive cases were HBV-DNA
positive indicating the close association of replicating HBV in
inducing AFP (Z = 2.02; p = 0.04 and 24.5% with CI 1—49%;
Table 2). Similarly analysis was made with regard to AFB1
positivity with or without viral positivity. Even though no
significant correlation could be made, 71.4% of HBV/AFB1
positive cases were also positive for AFP (Table 3).
Discussion
AFP is often elevated in HCC.8 Our study revealed 85.7% AFP
positivity among HBV/HCV co-infected HCC cases. In addi-
tion, the HBValone-associated HCC cases showed a positivity
of 62.9%. The study is in agreement with studies by others.8,9
In HBV and HCV negative HCC cases, the AFP positivity was
20.5%, and in HCV-associated HCC it was 17.6%, which seems
Table 2 Hepatitis B virus marker pattern observed in alpha-fetoprotein positive and negative, hepatitis B surface antigen (HBsAg)
positive hepatocellular carcinoma cases




Number Positive Number Positive
HBeAg 39 10 (25.6%) 23 7 (30.4%) Z = 0.11; p = 0.91 -
Anti-HBe 39 29 (74.4%) 23 16 (69.6%) Z = 0.11; p = 0.91 -
Anti-HBc IgM 12 9 (75%) 9 5 (55.6%) Z = 0.47; p = 0.63 -
HBV-DNA 39 35 (89.7%) 23 15 (65.2%) Z = 2.02; p = 0.04 24.5% (1—49%)
HDV 27 4 (14.8%) 16 6 (37.5%) Z = 1.33; p = 0.18 -
AFP, alpha-fetoprotein; CI, confidence interval; HBeAg, hepatitis B ‘e’ antigen; anti-HBe, anti-hepatitis B ‘e’ antigen antibodies; anti-HBc
IgM, anti-hepatitis B core antigen IgM antibodies; HDV, hepatitis D virus.
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quantitative levels of AFP were analyzed, the HBV/HCV co-
infected group and HBV alone positive HCC cases had sig-
nificantly elevated levels of AFP. Again, when AFP positivity
was analyzed based on the marker profile of HBV, 89.7% of
AFP positive cases were HBV-DNA positive, indicating the
close association of replicating HBV in inducing AFP. The
frequency and the extent of AFP elevation are greater in
HBsAg positive than HBsAg negative patients.10,11 We
recently reported that 58.1% of HCC cases showed aflatoxin
B1 (AFB1) in liver biopsies, but none was found from the
cirrhosis cases using an in-house immunoperoxidase staining
test.7 Further, we also reported that 68.8% of HBsAg negative
HCC cases and 46.1% of the HBsAg positive subjects were
concurrently positive for AFB1 in liver biopsy, which proves
that aflatoxins have a significant association with HCC in this
part of the tropical subcontinent using an in-house immuno-
histochemical method.7
The strong association between HBsAg and primary liver
cancer in countries where liver tumors are often AFP secre-
tors, suggests a role for HBV, not only in the etiology of the
cancer, but also in the reactivation of the gene encoding this
fetal protein. A report from the south of India has shown AFP
positivity to be higher in HBsAg positive HCC cases (69.9%)
and lower in HBsAg negative HCC cases (38.1%).12 The quan-
titative levels of AFP were also significantly higher in the HBV
positive (502 ng/ml) and HBV/HCV co-infected groups
(567.7 ng/ml) than in the other groups in our study. Similar
higher levels of AFP in HBV positive HCC cases (3200 ng/ml in
95%) have been reported by others.13 In contrast, other
reports from the West have shown that serum AFP levels in
HCC patients are not influenced by hepatitis B or C virus
pattern and that AFP dosage might not be advocated for HCC
diagnosis in non-cirrhotic patients.14 In addition, others have
postulated that the usefulness of AFP in the diagnosis of HCC
of viral etiology is limited and is more useful in HCC of non-
viral etiology.15Table 3 Alpha-fetoprotein levels in aflatoxin B1 tissue positive vs
AFB1 Numbers screened
HBsAg positive group (n = 15) Positive 7
Negative 8
HBsAg negative group (n = 16) Positive 11
Negative 5
HBsAg, hepatitis B surface antigen; AFB1, aflatoxin B1; AFP, alpha-fetopStudies on AFP levels in patients with HCC and other
benign and malignant liver diseases have shown that serum
AFP is greater than 400 ng/ml in 69% of patients with hepa-
toma.6 In none of 66 cases of cancer other than HCC was the
AFP level greater than 400 ng/ml. In 211 patients with non-
malignant liver disease, an AFP level greater than 400 ng/ml
was seen in only one patient, a person with chronic aggressive
hepatitis. These data suggest that in patients thought to have
HCC on clinical grounds, AFP levels about 400 ng/ml should
strongly confirm the presence of HCC by a tissue diagnosis.
However, clinicians should remember that some patients
with primary hepatic cancer will have normal AFP levels,
and normal or moderately elevated levels should not be used
to exclude the diagnosis of HCC.
In the present study AFP positivity was analyzed to check
the utility of thismarker in our HCC, cirrhosis, andCLD cases,
and to define the normal AFP levels in matched control
groups. It is generally accepted that a considerable number
of patients with acute and chronic hepatitis and cirrhosis
without malignancy might also have slight but significant
elevation of serum AFP.16,17 Frequent rises in adult serum
level of AFP are seen in patients with hepatitis and cirrhosis.
Positive rates (>10 or 20 ng/ml without detectable differ-
ences in the results) reported are 31—52% for acute hepa-
titis, 15—58% for chronic hepatitis, and 11—47% for
cirrhosis.6,16,18 Though there are reports on AFP positivity
in CLD and cirrhosis cases, in the present study none of our
CLD, cirrhosis, HBsAg carriers, and healthy control samples
showed AFP positivity. A major limitation is the smaller
sample size to assess the AFP levels in this group. Others
have analyzed histopathologically confirmed HCC cases and
have found that serum AFP is normal (<8.5 ng/ml) in 20%,
moderately elevated (8.5—300 ng/ml) in 48%, and consider-
ably elevated (>300 ng/ml) in 32% of cases.19 In a north
Indian study, the AFP levels were raised in 65% of the HCC
cases, the highest level recorded being 580 ng/ml.20 In
another south Indian study, elevated AFP levels were. negative hepatitis B virus positive and negative cases
AFP positivity Fisher’s exact test Mean (ng/ml)
5 (71.4%) p = 0.60 346
4 (50%) 557
6 (54.5%) p = 0.60 549
1 (20%) 568
rotein.
Alpha-fetoprotein and HCC e75observed in 47.4% of the cases.12 Our results corroborate
those of the south Indian study revealing a positivity of 45.4%
observed among HCC cases. The highest AFP level detected
in our HCC cases was 739 ng/ml. In acute hepatitis, transient
and simultaneous rises of serum AFP and transaminase or an
AFP rise shortly after the transaminase peak, have been
observed.18,21 In the present study AFB1 positive non-viral
HCC cases also showed higher levels of AFP (483 ng/ml). It
may be postulated that the levels of AFP might be indicative
of the severity of hepatocarcinogenesis, irrespective of the
hepatocarcinogen. This hypothesis is in line with the
other assumptions that viruses and certain other hepatotox-
ins may induce a distinct type of cell injury, leading to AFP
synthesis and release into the serum. Studies have shown
that AFP, AFP-L3, and des-g-carboxyprothrombin (DCP) are
the most useful serum tumor markers for the detection of
HCC, and their simultaneous determination could improve
the accuracy, especially in differentiating HCC from non-
malignant hepatopathy.22—26 Some clinical researchers have
indicated that the simultaneous determination of supple-
mentary markers especially glypican-3 (GPC3) along with
AFP could significantly increase the sensitivity in the diag-
nosis of HCC,23 which was not attempted in our study.
Further, themajor limitation of this study was that the study
failed to evaluate the factors closely associated with
tumors. It should be remembered that serum levels of AFP
reflect the size, number, and degree of differentiation of
HCC nodules.24,25
In conclusion, there has been no report on the AFP levels
of aflatoxin B1 positive HCC cases to the best of our knowl-
edge from the south Indian context. Based on the data
analyzed and investigations performed, we postulate that
serum AFP levels in HCC patients are influenced by HBV
pattern, in contrast to reports from the West, and could
be used in HCC diagnosis. We conclude that the overall
positivity pattern of AFP in HCC does indicate that higher
levels of AFP are observed with hepatitis virus positivity,
especially with HBV. Further studies are required to correlate
the serum levels of AFP with the size, number, and degree of
differentiation of HCC nodules.
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